Off goes VERV. The stock jumped up today. A closer look at what's happening:

Verve Therapeutics, Inc. (VERV) is trading 14% higher at $25.27 today. The price rose on news it was beginning a trial of it's gene editing medicines aiming to reduce heart disease. The price move came amid a flurry of thematic biotech buying over the last few weeks.

Verve Therapeutics, Inc. has been trading between a 52-week high of $78 and a 52-week low of $10.7. The stock has a market cap of $1.23 Billion.

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels.